Aegerion Pharmaceuticals' (Nasdaq:AEGR) Lomitapide Should be Catalyst

Citing the highly probable success of lomitapide, both commercially and regulatorially, Canaccord Genuity should be a strong catalyst for Aegerion Pharmaceuticals (Nasdaq:AEGR), according to Canaccord Genuity.

"We think lomitapide has a high chance of regulatory and commercial success. We think lomitapide will successfully complete the remaining safety portion of a pivotal trial and other small PK safety studies. Given HoFH’s unmet medical need, we think lomitapide will receive expedited review and approval in 2012 with a broad label. We think the drug will be appropriate for ~4,000-6,000 patients worldwide and predict worldwide peak sales of over $400M in HoFH alone," said Canaccord.

Canaccord Genuity maintains a "Buy" rating on Aegerion, which closed Thursday at $11 even. They have a price target of $16 on them.